Related Experiment Video
Updated: Apr 27, 2026
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.2K
KDM3B Predicts Expression Signature, Prognosis Value, and Immune Characteristics of Cancers: A Pan-Cancer Analysis
Liping Zhu1,2,3, Xiaoyan Peng1,2,3, Haile Yu2,3
1Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China, fjmu.edu.cn.
Biomed Research International
|April 26, 2026
Summary
Histone demethylase KDM3B is highly expressed in many cancers, correlating with poor prognosis and altered immune landscapes. This suggests KDM3B as a potential therapeutic target for cancer treatment.
Area of Science:
- Epigenetics and Cancer Biology
- Molecular Oncology
Background:
- Histone modifications, including methylation and acetylation, are crucial in cancer development.
- Histone demethylase KDM3B removes H3K9me1/2 methylation and is implicated in tumorigenesis.
- The specific role of KDM3B in cancer prognosis and formation requires further investigation.
Purpose of the Study:
- To investigate the expression patterns of KDM3B across various cancer types.
- To analyze the correlation between KDM3B expression and patient prognosis.
- To explore the relationship between KDM3B and the tumor immune microenvironment.
Main Methods:
- Pan-cancer analysis of KDM3B expression data.
- Utilized The Cancer Genome Atlas (TCGA) database.
- Correlated KDM3B expression with clinical outcomes and immune markers.
Main Results:
- KDM3B is significantly overexpressed in numerous cancer types.
- High KDM3B expression is associated with unfavorable patient prognosis.
- KDM3B expression correlates with immune checkpoint activity, lymphocyte infiltration, and immune landscape alterations.
Conclusions:
- KDM3B dysregulation is a common feature in cancer.
- KDM3B serves as a potential prognostic biomarker for cancer patients.
- Targeting KDM3B may offer a novel therapeutic strategy for cancer treatment.
